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Abstract
Background: Chlorproguanil2dapsone2artesunate (CDA) was developed as an affordable, simple, fixed-dose artemisininbased combination therapy for use in Africa. This trial was a randomized parallel-group, double-blind, double-dummy study to
compare CDA and artemether2lumefantrine (AL) efficacy in uncomplicated Plasmodium falciparum malaria and further define
the CDA safety profile, particularly its hematological safety in glucose-6-phosphate dehydrogenase (G6PD) -deficient patients.
Methods and Findings: The trial was conducted at medical centers at 11 sites in five African countries between June 2006
and August 2007. 1372 patients ($1 to ,15 years old, median age 3 years) with acute uncomplicated P. falciparum malaria
were randomized (2:1) to receive CDA 2/2.5/4 mg/kg once daily for three days (N = 914) or six-doses of AL over three days
(N = 458). Non-inferiority of CDA versus AL for efficacy was evaluated in the Day 28 per-protocol (PP) population using
parasitological cure (polymerase chain reaction [PCR]-corrected). Cure rates were 94.1% (703/747) for CDA and 97.4% (369/
379) for AL (treatment difference –3.3%, 95%CI –5.6, 20.9). CDA was non-inferior to AL, but there was simultaneous
superiority of AL (upper 95%CI limit ,0). Adequate clinical and parasitological response at Day 28 (uncorrected for
reinfection) was 79% (604/765) with CDA and 83% (315/381) with AL. In patients with a G6PD-deficient genotype (94/603
[16%] hemizygous males, 22/598 [4%] homozygous females), CDA had the propensity to cause severe and clinically
concerning hemoglobin decreases: the mean hemoglobin nadir was 75 g/L (95%CI 71, 79) at Day 7 versus 97 g/L (95%CI 91,
102) for AL. There were three deaths, unrelated to study medication (two with CDA, one with AL).
Conclusions: Although parasitologically effective at Day 28, the hemolytic potential of CDA in G6PD-deficient patients
makes it unsuitable for use in a public health setting in Africa.
Trial Registration ClinicalTrials.gov NCT00344006
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P. falciparum malaria (parasite count 2000 to 200,000 mL21); fever
at screening or within the previous 24 h; weight $7.5 kg;
hemoglobin $70 g/L or hematocrit $25%; willingness to comply
with study procedures; written or oral witnessed informed consent
from parent/guardian plus assent from patients $12 years old.
Subjects were excluded if they had: severe/complicated P.
falciparum malaria; known hypersensitivity/allergy to study treatments; known G6PD deficiency, methemoglobin reductase
deficiency, hemoglobin M/E, or porphyria; neonatal hyperbilirubinemia; concomitant medication associated with hemolysis or
hemolytic anemia; concomitant infection (including P. vivax,
P. ovale or P. malariae) or underlying disease that could compromise
efficacy evaluation; malnutrition (weight:height ratio ,23 standard deviations or ,70% of median National Center for Health
Statistics/WHO normalized reference values); received treatment
with another antimalarial that might have compromised study
treatment evaluation, or an investigational drug within 30 days or
5 half-lives; or participated previously in the study. A negative
pregnancy test was required from women of child-bearing age;
breastfeeding mothers were excluded.

Introduction
Malaria is clearly an insupportable burden upon sub-Saharan
Africa. Approximately 2102300 million clinical malaria episodes
and over 1 million deaths occur in this region annually [1]. The
majority of deaths are in children under 5 years. Initiatives in vector
control and avoidance have made some progress [2]. However, the
efficacy of the most affordable antimalarials is compromised by the
widespread emergence of P. falciparum resistance to these agents.
Artemisinin-based combination therapy (ACT) is clinically
effective, and may reduce malaria transmission and the potential
for the development and spread of resistance [3,4]. ACT is
recommended by the World Health Organization (WHO) Global
Malaria Programme as first-line antimalarial treatment in Africa,
though achieving an acceptable cost and dosing simplicity for
ACT has been difficult [5].
Chlorproguanil2dapsone2artesunate (CDA) was developed as
an affordable, fixed-dose ACT for use in Africa. Once-daily dosing
over three days and good activity of the chlorproguanil–dapsone
(CPG2DDS) component suggested a promising combination
[6,7]. Initial CDA studies indicated a safety profile consistent with
CPG2DDS [6,7]. Hemolysis and methemoglobinemia are known
adverse effects of dapsone, and are generally mild and self limiting,
though hemolysis is more pronounced in subjects with glucose-6phosphate (G6PD) deficiency [8]. G6PD deficiency is an X-linked
trait, consequently more common in men than women; heterozygous women display mosaicism [9]. Exposure to oxidative stress
can induce hemolysis in G6PD-deficient subjects [10]. However,
the potential for dapsone, an oxidant drug, to cause clinically
relevant hemolysis in malaria patients with G6PD deficiency has
not been well characterized [7,11,12].
Artemether2lumefantrine (AL) is the current gold standard
ACT. The six-dose regimen is highly effective and represents a
challenging comparator for any new agent [13–20]. Study
objectives were to compare CDA and AL efficacy in uncomplicated P. falciparum malaria and further define the CDA safety
profile, in particular, its hematological safety in G6PD-deficient
malaria patients. A randomized, parallel-group, double-blind,
double-dummy, multicenter, Phase III study was conducted to
demonstrate non-inferiority of CDA to AL based on parasitological cure rate (adjusted for polymerase chain reaction [PCR]
genotyping) at study Day 28. Patients were young children and
adolescents, representing the most clinically vulnerable population.

Interventions
At screening, a full medical history was obtained and a clinical
examination undertaken. Eligible patients were randomized (2:1)
to receive CDA (GlaxoSmithKline, Greenford, UK) 2/2.5/4 mg/
kg/day once daily for three days, administered according to
predefined dosing charts, or six-dose AL (Novartis Pharma AG,
Basel, Switzerland). One 20/120 mg AL tablet was given for
patients weighing 5–15 kg, two for 15–,25 kg, three for 25–
,35 kg and four for $35 kg, taken at study start (Day 0), 8 h later
and then twice daily for two days. AL was dosed with milk.
Matching placebos were administered to maintain blinding.
Administration of therapy was directly observed and if vomiting
occurred within 30 mins of dosing, the patient was re-dosed. If
vomiting occurred again, the patient was treated with rescue
medication (as per local clinical practice guidelines) and followed
until Day 42.
Patients remained hospitalized until Day 3, returning for followup visits on Days 7, 14, 28 and 42. Field workers visited patients at
home on Days 4, 5 and 6 to ensure they remained well. Clinical
evaluation and temperature recording was performed before first
dose, during therapy and at all clinic follow-up visits. Subjects failing
therapy at any time during the study received rescue medication
immediately and were followed until Day 42 or resolution.
Venous blood samples (2 mL) were obtained for hematology
assessments at screening and on Days 1, 2, 3, 7, 14, 28 and 42 and
for standard clinical chemistry tests at pre-dose, on Days 3 and 42,
and on Days 14 and 28 if previous assessment values were
abnormal.
Asexual parasite and gametocyte counts were performed at
screening, at pre-dose, every 8 h during the in-patient stay until
discharge on Day 3 and at follow-up visits on Days 7, 14, 28 and
42. At each time point, two thick and one thin film were prepared
and parasite densities determined by examination of a thick blood
slide (10 mL thumb prick), according to WHO methods [21].
Recrudescence was distinguished from reinfection with PCR
genotyping, comparing pre-dose parasites versus post-Day 7
isolates using P. falciparum msp-1, msp-2, and glurp [22,23].
A pre-dose blood sample (10 mL) was collected onto pre-printed
filter paper for G6PD genotype analysis at two laboratories
(Shoklo Malaria Research Unit, Mae Sot, Thailand and Kenya
Medical Research Institute, Nairobi, Kenya). Following DNA
extraction, fragment amplification using PCR primers for loci 376
ARG, 202 GRA, 542 GRT, 680 GRT and 968 TRC allowed

Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.

Ethics statement
This study was conducted in accordance with Good Clinical
Practices, applicable regulatory requirements, and the Declaration
of Helsinki. Approval was obtained from each participating
center’s ethics committee or institutional review board and the
WHO Special Programme for Research and Training in Tropical
Medicine. An Independent Data Monitoring Committee (IDMC)
was convened and planned to conduct two interim safety analyses.
The IDMC appointed an independent end-point reviewer
(blinded to treatment assignment).

Participants
Male and female patients ($1–,15 years old) who met the
following criteria were eligible for enrolment: acute uncomplicated
PLoS ONE | www.plosone.org
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recognition of the wildtype (G6PD B) and the common African
mutations G6PD A and A– [24–27]. G6PD phenotype was
analyzed using pre-dose hematology samples at a central
laboratory (Synexa, Cape Town, South Africa) by commercial
NADPH fluorescence test (Trinity Biotech, Wicklow, Ireland).
G6PD genotyping and phenotyping results were not available to
investigators until after study completion.

Randomization 2 Sequence generation

Objectives

GlaxoSmithKline generated the randomization schedule comprising blocks of six patients by center.

The objective of this trial was to compare CDA and AL efficacy
in uncomplicated P. falciparum malaria and further define the CDA
safety profile, in particular its hematological safety in G6PDdeficient patients.

Randomization 2 Allocation concealment and
implementation

and 325 evaluable patients, respectively, were required using a
one-sided hypothesis test at a 2.5% significance level and a 7%
non-inferiority margin. Allowing for 30% loss, target recruitment
was 930:465 patients CDA:AL. No multiplicity was associated
with this single primary comparison.

Randomization was done at the study site by a telephone call to
the automated Registration and Medical Ordering System
(RAMOS). An individual patient’s code could be accessed by an
investigator via RAMOS in an emergency.

Outcomes
The primary efficacy endpoint was parasitological cure rate
(PCR-corrected) at Day 28, defined as eradication of initial
malaria infection by Day 7 plus aparasitemia through to Day 28.
Parasitological cure was also evaluated at Days 14 and 42 as a
secondary outcome.
PCR-corrected parasitological cure was the standard method
for assessing antimalarial efficacy at the time that the study was
designed. However, publication of the WHO 2003 guidelines for
evaluating antimalarials led to the protocol being amended to
include adequate clinical and parasitological response (ACPR) as a
secondary outcome [21]. ACPR and PCR-corrected ACPR
(ACPRp) at Days 14, 28, and 42 were derived as per WHO
2003 definitions [21], in brief: ACPR is the absence of
parasitemia, irrespective of axillary temperature without previous
treatment failure. Early treatment failure is the development of
severe malaria by Day 3 with parasitemia, or parasitemia on Day 2
higher than on Day 0, or parasitemia on Day 3 with fever, or Day
3 parasitemia $25% of Day 0 count. Late clinical failure is the
development of severe malaria after Day 3 with parasitemia, or
parasitemia and fever from Day 4228, without previous early
treatment failure. Late parasitological failure is parasitemia on
Day 7228 with fever, without previous early treatment failure or
late clinical failure.
Other secondary outcomes included: asexual parasite and
gametocyte counts; mean parasite clearance time (time at which
asexual parasites became undetectable and remained so for
$48 h); and mean fever clearance time (time at which
temperature normalized and remained so for $48 h).
Adverse events were defined as any unfavorable and unintended
sign (including an abnormal laboratory test result), symptom, or
disease (new or exacerbated) temporally associated with the use of
a medicinal product. Adverse events were recorded at all clinic
visits and coded using MedDRA (Version 10.1). Serious adverse
events were defined as: death or life-threatening illness; resulting in
hospitalization or prolongation of hospitalization; significantly
disabling/incapacitating; congenital anomaly; hemoglobin decrease $40% versus baseline; hemoglobin ,50 g/L; blood
transfusion; methemoglobin $20% or $10 to ,20% with
associated clinical symptoms; or any other event considered
significant by the investigator.
Hemoglobin safety. A composite ‘hemoglobin safety’
endpoint was defined prospectively as: hemoglobin decrease of
$40 g/L or $40% versus baseline or hemoglobin ,50 g/L or
blood transfusion.

Blinding
Investigators, technicians performing microbiological assessments and patients were blinded to study treatments.

Statistical analysis
The intent to treat (ITT) population included all randomized
patients who received at least one dose of study medication. The
PP population was a sub-set of the ITT population including
patients who did not violate the protocol in a way that might
impact the efficacy analysis.
The primary analysis was performed on the Day 28 PP
population. The difference in PCR-adjusted parasitological cure
rates and the 95% confidence interval (CI) was calculated using
the normal approximation to the binomial distribution. A similar
analysis was performed for the ITT population and for ITT
observed cases (i.e. excluding missing data). For the PP population,
a logistic regression model was fitted to estimate treatment effect
adjusted for country, age (,5 years, 5–,15 years), and baseline
parasitemia (categorized by #33%, .33–,67%, and $67%
quantile). Descriptive statistics were provided for secondary
endpoints (PP and ITT populations) and safety outcomes (ITT
population).
For patients who were failures owing to new infections
(determined using PCR), both PP and ITT analyses deemed
these subjects to be successes at that time point. However, at
subsequent time points, the PP analyses considered these patients
as missing and the ITT analysis assumed that they were failures.
Patients with missing data at the relevant time point were
excluded from PP analyses of efficacy data (PCR-adjusted
parasitological cure and ACPR). In the ITT analyses, treatment
failure was imputed for missing data. For example, a patient with no
Day 28 parasite count would be excluded from the primary endpoint
and ACPR PP analyses but included as a treatment failure in the
supporting ITT analyses. If a patient was missing a parasite
assessment before Day 28, this would not affect assessment of Day 28
parasitological cure, whereas for ACPR, treatment failure could not
be assessed and the patient would be excluded from the PP analysis
with an imputation of failure in the corresponding ITT analysis.
Comparisons of CDA and AL for the hemoglobin safety
composite endpoint and changes in hemoglobin versus baseline
were analyzed by the following G6PD genotype categories: G6PD
normal, G6PD heterozygous females, and G6PD deficient
(hemizygous A2 males and homozygous A2/A2 females).
Logistic regression modeling was used to quantify the impact of
G6PD genotype, weight, age, baseline hemoglobin, baseline
parasitemia, and treatment on hemoglobin safety endpoints.

Sample size
The study was designed with $90% power to test the hypothesis
that CDA was non-inferior to AL for the primary outcome
measure. Assuming efficacy of 93% for CDA and 95% for AL, 650
PLoS ONE | www.plosone.org
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Table 1. Demographic and baseline clinical characteristics of
the randomized (ITT) population.

Characteristic

CDA (N = 914)

AL (N = 458)

Male sex, n (%)

457 (50)

245 (53)

Mean age, years (SD) [range]

4.2 (3.0) [1–14]

4.0 (2.9) [1–13]

Number aged 1 to ,5 years, n (%)

586 (64)

300 (66)

Number aged 5 to ,15 years, n (%)

328 (36)

158 (35)

Mean weight, kg (SD) [range]

16.2 (7.1) [8–62]

16.0 (6.8) [8–59]

Geometric mean parasitemia (mL21)
(range)

23378 (0–389415)*

22383 (185–705600)

Mean hemoglobin, g/L (SD) [range] 100 (15) [58–145]**

100 (15) [47–158]**

*

Three patients in the CDA group had parasites identified at screening, were
enrolled, randomized and treated, though later examination revealed that the
parasites were P. malariae and P. ovale. Consequently, their P. falciparum
parasite counts were zero.
**
At some sites, screening hemoglobin level was determined using a rapid test
(Haemacue, Downfield, UK), with subsequent checking using a coulter
counter. Twelve subjects in the CDA group and five in the AL group had
haemacue tests of $70 g/L with subsequent coulter counter hemoglobin
values of ,70 g/L. Coulter counter values are reported here.
doi:10.1371/journal.pone.0006682.t001

significantly different from Hardy2Weinberg proportions. This is
not surprising as the proportion of A2 hemizygous males (in
centers with data for .1 male) ranged between 2/26 (7.7%) in
Ibadan and 4/19 (21.1%) in Bagamoyo. Phenotypic data were
available for only 632/1372 (46%) patients.

Numbers analyzed
Figure 1 shows the trial profile. The PP population comprised
796/914 (87%) patients in the CDA group and 400/458 (87%) in
the AL group. The primary analysis was conducted using the Day
28 PP population and 747/914 (82%) patients in the CDA group
and 379/458 (83%) in the AL group were evaluable at this time
point. At
Table 2. G6PD genotype (ITT population).

Figure 1. Trial profile.
doi:10.1371/journal.pone.0006682.g001

Category

Results
Participant flow
Participant flow is shown in Figure 1. The ITT population
comprised all 1372 randomized patients; 914 assigned to CDA
and 458 to AL. The proportion of premature withdrawals was
similar in each treatment group (Figure 1).

Recruitment
The trial was conducted between June 2006 and August 2007 at
health centers in Bobo-Dioulasso, Burkina Faso; Kintampo,
Ghana; Eldoret, Kilifi and Pingilikani, Kenya; Ibadan, Enugu,
Jos and Calabar, Nigeria; and Bagamoyo and Kiwangwa,
Tanzania.

CDA

AL

Males

(N = 457)

(N = 245)

(N = 702)

Missing, n (%)

69 (15)

30 (12)

99 (14)

Genotype, n (%)

388 (85)

215 (88)

603 (86)

A

85 (22)

46 (21)

131 (22)

B

239 (62)

139 (65)

378 (63)

A2

94 (16)

64 (16)

30 (14)

(N = 457)

(N = 213)

(N = 670)

Missing, n (%)

45 (10)

27 (13)

72 (11)
598 (89)

Genotype, n (%)

Baseline characteristics were similar between treatment groups;
all patients were of Black African ethnicity (Table 1). G6PD
genotype was available for 1201 patients; 94/603 (16%) were A2
hemizygous males and 22/598 (4%) were A2/A2 homozygous
females (i.e. G6PD-deficient) (Table 2). Female genotypes were

Total

Females

Baseline data

PLoS ONE | www.plosone.org

Genotype*

412 (90)

186 (87)

A/A

16 (4)

13 (7)

29 (5)

A/B

101 (25)

32 (17)

133 (22)

B/B

156 (38)

92 (49)

248 (41)

A/A2

41 (10)

13 (7)

54 (9)

B/A2

82 (20)

30 (16)

112 (19)

A2/A2

16 (4)

6 (3)

22 (4)

*

Percentages exclude missing data.
doi:10.1371/journal.pone.0006682.t002
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98.0% (148/151), treatment difference 23.9%, 95%CI 27.4,
20.4); Tanzania, CDA 91.9% (171/186), AL 95.6% (86/90),
treatment difference 23.6%, 95%CI 29.4, 2.2.
Secondary outcomes: ACPR and ACPRp. ACPR at Day
28 in the PP population was 79% for CDA and 83% for AL;
ACPRp was 93% and 94%, respectively (Table 4). The
proportions of early treatment failures, late clinical and late
parasitological failures were similar between treatment groups
(Table 4). Reinfection rates were similar for CDA and AL; 14%
and 12% at Day 28, respectively, and 22% for both study drugs at
Day 42 (Table 4).
Secondary outcomes: parasite and fever clearance. Asexual parasite counts decreased rapidly in both treatment groups; by
16 h post first treatment dose, parasite counts had declined by 99%
in both groups. Mean (SD) parasite clearance time was 23.5 (11.0) h
(N = 909) for CDA and 26.2 (11.5) h (N = 456) for AL (ITT
population). For patients with baseline fever, mean fever clearance
time (SD) was: 28.7 (23.3) h (N = 538) and 26.6 (22.2) h (N = 250)
(ITT population).
Secondary outcomes: gametocyte prevalence. Gametocytes were present at baseline in 25/912 (3%) patients in the CDA
group and in 10/458 (2%) in the AL group (ITT population). The
proportion of gametoyctemic patients decreased throughout the
study similarly in both treatment groups. For both the PP and ITT
population analyses, the geometric means ranged between 1.0 and
1.1 parasites/mL throughout the study in both treatment groups.
The median gametocyte counts were 0 prior to dosing and at each
time point following dosing for both treatment groups.

Day 14, there were 787/914 (86%) evaluable patients in the
CDA group and 393/458 (86%) in the AL group and at Day 42
661/914 (72%) and 332/458 (72%), respectively.

Outcomes and estimation
Primary outcome: parasitological cure at Day
28. Parasitological cure (PCR-corrected) at Day 28 in the PP

population was 94.1% for CDA and 97.4% for AL (treatment
difference 23.3%, 95%CI 25.6, 20.9; Table 3). CDA met the
non-inferiority criterion of a lower 95%CI of $27%. However,
an upper 95%CI of ,0 indicated simultaneous superiority of AL.
Non-inferiority was maintained in the ITT analysis (Table 3).
The ITT observed cases sensitivity analysis also showed CDA noninferiority. Logistic regression performed on the Day 28 PP
population suggested superiority of AL versus CDA, odds ratio
(OR) 2.3 (95%CI 1.2, 4.7; P = 0.018), and no interaction with
country, age or baseline parasitemia. The model provided overall
adjusted cure rate of 95.2% for CDA and 97.9% for AL. The
standard errors of these estimates were obtained using the delta
method to provide the 95% confidence interval for treatment
difference (22.7%, 95%CI 24.9, 20.5). This analysis supports the
primary unadjusted analysis where CDA met the non-inferiority
criterion of a lower 95%CI of $27%.
For parasitological secondary endpoints (Table 3), CDA was
non-inferior to AL at Day 14 but not at Day 42 (PP population).
Outcomes were similar in the ITT population (Table 3). PP
population covariate analysis at Day 28 revealed no significant
interaction with treatment for country (P = 0.834), age (P = 0.479),
or baseline parasitemia (P = 0.179).
This study was not powered to compare treatments for individual
countries. Per-country Day 28 cure rates (PP population) were as
follows: Ghana/Burkina Faso, CDA 95.7% (110/115), AL 98.3%
(58/59), treatment difference 22.7%, 95%CI 27.6, 2.3; Kenya,
CDA 95.5% (150/157), AL 97.5% (77/79), treatment difference
21.9%, 95%CI 26.7, 2.8; Nigeria, CDA 94.1% (272/289), AL

Ancillary analysis
Compliance with medication. A subject was considered
compliant with study treatment if they received the treatment to
which they were randomized as well as the correct dose for their
body weight on all three dosing days. Compliance with study
medication was 94% for both treatment groups.

Table 3. PCR-corrected parasitological cure at Day 28 (primary endpoint), Day 14 and Day 42 (secondary endpoints).

Parasitological cure, n (%) at:

PP population

ITT population

CDA (N = 796)*

AL (N = 400)*

CDA (N = 914)**

AL (N = 458)**

758/787 (96.3)

376/393 (95.7)

834 (91.2)

415 (90.6)

Day 14
PCR corrected
Treatment difference (95%CI)

0.6 (21.8, 3.0)

0.6 (22.6, 3.9)

Day 28
PCR corrected

703/747 (94.1)

Treatment difference (95%CI)

369/379 (97.4)

758 (82.9)

23.3 (25.6, 20.9)

391 (85.4)
22.4 (26.5, 1.6)

Day 42
PCR corrected
Treatment difference (95%CI)

591/661 (89.4)

311/332 (93.7)
24.3 (27.8, 20?7)

647 (70.8)

336 (73.4)
22.6 (27.6, 2.4)

*

In the PP analysis, patients with missing data were excluded and patients with new infections (determined by PCR) were considered successes at the first time point
that this outcome was recorded, but were excluded thereafter.
At Day 14, nine patients were non-evaluable in the CDA group: two earlier new infections (0.25%), three without PCR at Day 14, and four for ‘other’ reasons. In the AL
group, seven patients were non-evaluable: one earlier new infection (0.25%), five without PCR at Day 14, and one ‘other’.
At Day 28, 49 patients were non-evaluable in the CDA group: 26 earlier new infections (3.3%), ten without PCR at Day 28, and 13 ‘other’. In the AL group, 21 patients
were non-evaluable: ten earlier new infections (2.5%), seven without PCR at Day 28, and four ‘other’.
At Day 42, 135 patients were non-evaluable in the CDA group: 109 earlier new infections (13.7%), ten without PCR at Day 42, and 16 ‘other’. In the AL group, 68 patients
were non-evaluable: 56 earlier new infections (14.0%), five without PCR at Day 42, and seven ‘other’.
**
In the ITT analysis, patients with missing data were treated as failures. Patients with new infections (determined by PCR) were considered successes at the first time
point that this outcome was recorded and as failures thereafter.
doi:10.1371/journal.pone.0006682.t003
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Table 4. WHO-defined 2003 endpoints for assessing antimalarial therapy: ACPR and ACPRp.

Treatment response, n/N (%) at:

PP population

ITT population

CDA (N = 796)*

AL (N = 400)*

CDA (N = 914)

AL (N = 458)

8/760 (1)

6/381 (2)

65 (7)

37 (8)

Day 28
Early treatment failure**
Late clinical failure

41 (5)

16 (4)

40 (4)

17 (4)

Late parasitological failure

112 (14)

44 (11)

122 (13)

49 (11)

ACPR

604/765 (79)

315/381 (83)

687 (75)

355 (78)

ACPRp{

708/765 (93)

360/381 (94)

791 (87)

403 (88)

Day 42
Late clinical failure

69 (9)

28 (7)

66 (7)

28 (6)

Late parasitological failure

167 (21)

75 (19)

179 (20)

82 (18)

ACPR

527/771 (68)

275/384 (72)

604 (66)

311 (68)

697/771 (90)

358/384 (93)

774 (85)

398 (87)

ACPRp

{

*

For the PP population, patients with missing data or indeterminate results were excluded 2 the denominator shows the number of evaluable patients. For the ITT
population, patients with missing or indeterminate PCR results were treated as failures. For ACPRp, in the PP and ITT analysis, patients with new infections were
considered successes at that time point. However, at subsequent time points, the PP analyses considered these patients as missing and the ITT analysis assumed that
they were failures.
**
Early treatment failure is the same for Day 42.
{
ACPRp is ACPR corrected using PCR genotyping for reinfection. Reinfection rate = ACPRp 2 ACPR.
doi:10.1371/journal.pone.0006682.t004

anemia, three hemoglobin decreased). In the AL group, malaria
was the most common serious adverse event (7/458 [2%]). All
serious adverse events in the AL group were in G6PD-normal
patients, except one case of malaria in a heterozygous female.
Hemoglobin laboratory analysis. Overall in the ITT
population, mean hemoglobin concentrations decreased versus
baseline from Day 1 for both treatment groups (Figure 2a), and
were slightly lower for CDA versus AL on Days 3, 7 and 14
(Figure 2a). For G6PD-normal and female heterozygote patients,
the maximum hemoglobin decrease was similar for both study
drugs, though recovery to baseline levels was slower with CDA
(Figure 2b,c). For G6PD-deficient patients, declines in hemoglobin
concentration were more marked with CDA versus AL at Days 3,
7 and 14 (Figure 2d). The mean hemoglobin nadir for CDA in
G6PD-deficient patients was 75 g/L (95%CI 71, 79) at Day 7
versus 97 g/L (95%CI 91, 102) for AL. The mean hemoglobin
nadir in G6PD-deficient patients for AL was 93 g/L (95%CI 87,
99) occurring at Day 3 versus 82 g/L (95%CI 79, 85) for CDA.
The proportion of patients with a decrease in hemoglobin
concentration versus baseline of $20 g/L was 305/914 (33%)
with CDA and 112/458 (24%) with AL. By G6PD genotype, this
endpoint occurred in 173/597 (29%) normal, 45/123 (37%)
heterozygote and 45/80 (56%) deficient patients in the CDA
group and in 77/322 (24%), 9/43 (21%) and 12/36 (33%),
respectively in the AL group. Figure 3 shows the relative frequency
distribution for maximum hemoglobin decrease versus baseline.
CDA and AL had similar profiles in G6PD-normal patients
(Figure 3a), whereas for G6PD-deficient patients, CDA data were
left-shifted versus AL, i.e. there was a greater relative frequency of
clinically significant hemoglobin decreases with CDA (Figure 3c).
Hemoglobin composite safety endpoint. Occurrences of
the hemoglobin safety endpoint in G6PD-deficient patients were
35% (28/80) with CDA versus 0% with AL (Table 6). A post-hoc
analysis for risk factors associated with occurrences of the
composite endpoint found significant effects for G6PD-deficiency
(OR 16.3, 95%CI 8.6, 31.2), treatment with CDA versus AL (OR
5.1, 95%CI 2.1, 12.4) and baseline parasitemia (OR 2.3, 95%CI

Adverse events
The proportion of treatment-emergent adverse events due to any
cause was similar between the treatment groups: 476/914 (52%) in
the CDA group and 220/458 (48%) in the AL group. The majority
of adverse events were mild to moderate in intensity (96% for CDA,
98% for AL). Adverse events reported by investigators as probably
or possibly drug-related occurred in 184 (20%) patients in the CDA
group and 86 (19%) in the AL group (Table 5).
Serious adverse events were reported for 63/914 (7%) patients
in the CDA and 15/458 (3%) patients in the AL group. In the
CDA group, serious adverse events most likely related to oxidative
hemolysis occurred in 46/914 (5%) of patients versus 3/458
(,1%) in the AL group. In G6PD-deficient patients receiving
CDA, 26/80 (33%) had such events (six cases of hemoglobin
decreased, seven hematuria/hemoglobinuria [these were not
always differentiated], two hemolysis, two hemolytic anemia and
one blood methemoglobin) compared with 10/597 (2%) for G6PD
normal (seven anemia, two hemoglobin decreased, one intravascular hemolysis) and 5/123 (4%) for female heterozygotes (two
Table 5. Most frequent investigator-reported treatmentemergent drug-related adverse events reported in the ITT
(safety) population ($2% of patients in either treatment
group).

Preferred term, n (%)

CDA (N = 914)

AL (N = 458)

Reticulocyte count decreased

79 (9)

44 (10)

Anemia

24 (3)

9 (2)

Hemoglobin decreased

24 (3)

7 (2)

Vomiting

14 (2)

4 (,1)

Thrombocytopenia

15 (2)

3 (,1)

Patients with at least one drug-related
adverse event

184 (20)

86 (19)

doi:10.1371/journal.pone.0006682.t005
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Figure 2. Mean hemoglobin (695%CI) over time (a) for the ITT population and by G6PD genotype: (b) normal; (c) female
heterozygous; (d) deficient (male hemizygous and female homozygous). Day 0 are screening (baseline) values.
doi:10.1371/journal.pone.0006682.g002

1.3, 4.3). There was no increased risk in G6PD heterozygous
females, and no effect of age, weight or baseline hemoglobin.
Fourteen blood transfusions were performed for a significant
decrease in hemoglobin, all in the CDA group: 12 in G6PDdeficient patients, one in a heterozygous female, and one in a
G6PD-normal patient. One subject in the CDA group received a
transfusion for treatment of sickle cell crisis (G6PD status
unknown). A further subject in the CDA group (hemizygous male)
was hospitalized on Day 6 requiring a blood transfusion
(hemoglobin 38 g/L), though blood was not available. This
patient subsequently recovered under close observation and
supportive treatment with hematinics.
Mortality and withdrawals. Three deaths occurred during
the study: two in the CDA and one in the AL group; none were
attributed to study treatment by the investigator. In the CDA
group, a 2-year-old female had severe malaria and severe herbal
intoxication at Day 23 and 24 and died on Day 24; a 4-year-old
male with sickle cell anemia with crisis and severe sepsis was
inadvertently recruited into the study, withdrawn on Day 1 and
PLoS ONE | www.plosone.org

transfused and died on Day 2. In the AL group, a 1-year-old male
had severe pyrexia at Day 26 and died on Day 29. There were
three other withdrawals because of adverse events, two with CDA
(vomiting and febrile convulsion) and one with AL (hematuria), all
of which resolved.

Discussion
For the primary endpoint of this trial, parasitological cure at
Day 28 (PP population), CDA was highly efficacious (94%). CDA
was non-inferior to AL, but AL was simultaneously superior to
CDA. An adjusted logistic regression analysis (PP population) also
showed AL superiority. Non-inferiority of CDA to AL for the
primary efficacy endpoint was not maintained at Day 42. These
results confirm the high efficacy of AL in Africa [13–20].
It was notable that there was no difference in reinfection rates
between the two treatment groups. A recent comparison of CDA
and AL also found no difference in reinfection rates [28].
Lumefantrine has a half-life of 324 days, with concentrations
7
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Table 6. Occurrences of the hemoglobin safety composite
endpoint (hemoglobin decrease of $40 g/L or $40% versus
baseline or hemoglobin ,50 g/L or blood transfusion) by
G6PD genotype in the ITT (safety) population.

G6PD genotype, n/N (%)

CDA

AL

Normal

18/597 (3)

5/322 (2)

Female heterozygous

7/123 (6)

1/43 (2)

G6PD deficient*

28/80 (35)

0/36

Missing

11/114 (10)

3/57 (5)

Total

64/914 (7)

9/458 (2)

*
Deficient is male hemizygous G6PD A2 and female homozygous G6PD A–/A2.
doi:10.1371/journal.pone.0006682.t006

above inhibitory concentrations for 10?5 days [29]. Despite the
short half-life for CPG (35 h) and DDS (27 h), the duration of
parasitocidal activity against susceptible parasites is approximately
3210 days, depending on parasite strain [30]. Thus, the drugs are
potentially pharmacodynamically more similar than their pharmacokinetics would suggest.
Although this study was designed primarily to assess efficacy, the
most clinically important findings relate to safety, specifically
G6PD-related hemolysis in the CDA group. The 2:1 CDA:AL
randomization schedule was chosen to provide adequate data for a
meaningful analysis of CDA safety. Also, we defined a composite
hemoglobin safety endpoint based on laboratory data for
hemoglobin declines of clinical concern and blood transfusion
events. Overall, the main risk factors associated with the composite
endpoint were G6PD deficiency versus G6PD normal (OR 16.3,
95%CI 8.6, 31.2) and CDA treatment versus AL (OR 5.1, 95%CI
2.1, 12.4). In G6PD-deficient patients (hemizygous males and
homozygous females), 35% met the composite endpoint criteria
with CDA versus none with AL. Of particular concern was that
12/15 patients requiring blood transfusion were G6PD-deficient,
and all in the CDA group.
This study was not powered to detect a difference in
hematological safety in G6PD-deficient patients between treatment groups. However, subjects meeting the composite hemoglobin safety endpoint would clearly require hospital-based interventions. These are often difficult to access for the majority of malaria
patients in sub-Saharan Africa. Based on the composite endpoint
data, CDA has an unacceptable risk:benefit profile versus AL for
the treatment of malaria in G6PD-deficient patients. Consequently, this population should not be exposed to CDA.
The prevalence of G6PD deficiency in this study was 16%
hemizygous males and 4% homozygous females; a substantial subpopulation. The lowest prevalence of G6PD deficiency was 7.7% in
Ibadan, though this is considerably lower than previous estimates,
generally in excess of 20% [31]. Additionally, 14% of patients were
heterozygous females, only identifiable by genotyping.
G6PD phenotyping and genotyping are not generally available
in Africa. Even if G6PD-deficient patients could be excluded, posthoc regression analysis found that in G6PD-normal patients, the
risk of a $20 g/L hemoglobin decrease versus baseline was
slightly increased with CDA versus AL (OR 1.4, 95%CI 1.01,
1.96). The clinical relevance of this small difference is debatable,
but further undermines CDA utility, given the availability of
alternative agents. CDA was developed for use in Africa as a safe,
affordable, effective and simple antimalarial. As these conditions
cannot be met, the Joint Development Team decided to terminate
CDA development and withdraw CPG2DDS licenses.

Figure 3. Relative frequency distribution for the maximum
decrease in hemoglobin versus baseline at any time during the
study, or minimum increase in hemoglobin versus baseline if
hemoglobin values were greater than baseline throughout the
study, by G6PD genotype: (a) normal; (b) female heterozygous;
(c) deficient (male hemizygous and female homozygous).
doi:10.1371/journal.pone.0006682.g003
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G6PD genotype data are required for an adequate analysis of
hemolytic potential in the G6PD-deficient sub-population.
A recently published study conducted in Rwanda comparing
CDA versus amodiaquine (AQ) plus SP for the treatment of
uncomplicated malaria is also informative [35,36]. In this study,
G6PD genotyping was available for the majority of patients. Packed
cell volume (hematocrit) was evaluated, so direct comparison to our
results is not possible. Although both CDA and AQ+SP caused mild
hemolysis in G6PD-normal patients, hemolysis was more profound
in G6PD-deficient patients with CDA, but not AQ+SP. However,
in light of its continued widespread use, the risk:benefit of SP with
regard to hematological safety in G6PD-normal and -deficient
malaria patients needs to be properly investigated versus a nonhemolytic comparator, such as AL.
One important question is whether the hemolysis observed here
is new to CDA or would have been seen with CPG2DDS versus
AL. Preliminary results from a second Phase III clinical trial of
similar design indicate no major differences in hematological safety
between CDA and CPG2DDS (personal communication P.
Winstanley).
There were some limitations in the hematological data collected
in this study. A validated methemoglobin test, suitable for clinic
use, was only available towards the end of the study. Consequently, only 32 patients from two centers (Eldoret and Calabar) had
screening and post-baseline methemoglobin data. Collection of
reticulocyte data was not automated and there was no quality
control process. On examination, reticulocyte percent and
absolute data could not be interpreted and the results are not
presented. G6PD phenotypic data were only available for 632/
1372 (46%) patients because of logistical problems in transporting
samples to a central laboratory within a narrow time window and
data are not presented. The difficulties in obtaining sufficient
G6PD phenotype data quickly hampered assessment of safety
within the G6PD-deficient population by the IDMC during the
recruitment phase. For the limited data available, concordance of
a G6PD-deficient phenotype with genotype in hemizygous males
was 271/313 (87%), and phenotype findings supported genotype
findings with respect to both G6PD-deficiency prevalence and
hemoglobin safety.

Overall evidence
Although we knew that there would be some hemolytic effect of
dapsone, the magnitude of the difference in this effect between
CDA and AL in G6PD-deficient patients was unexpected [11].
Phase II studies with CDA in children of unknown G6PD status
had been encouraging, with decreases in hemoglobin until Day 3
but with recovery by Day 7, surpassing baseline values by Day 14
[6]. There was also marginally better hemoglobin recovery in the
4 mg/kg artesunate-containing arm versus CPG2DDS alone,
suggesting that the majority of the hemolysis was due to suboptimal antimalarial therapy [6].
In this study, comparison of the timecourse for hemoglobin
decline with CDA and AL is instructive (Figure 2). For AL, regardless
of G6PD status, the nadir in hemoglobin concentration occurred at
or before Day 3. With CDA, for G6PD normal and female
heterozygotes, hemoglobin was significantly lower than with AL at
Day 7 only. This was probably caused by dapsone-related shortening
of erythrocyte lifespan. However, in G6PD-deficient patients, the
decrease in hemoglobin with CDA was more marked, with a nadir at
Day 7, and was significantly different from AL from Day 3 until Day
30. This clearly shows the effect of G6PD deficiency when oxidative
and potentially hemolytic drugs are administered.
Dapsone had been used in malaria and leprosy for many years
with no major safety concerns [32–34]. Thus, previous studies of
CPG2DDS without artesunate did not prospectively include
G6PD genotyping or phenotyping. Also, concerns on frequent
blood sampling in young children led to less comprehensive
hemoglobin assessments than in the current study. Comparison of
our data with CPG2DDS clinical trials is, therefore, problematic.
In the CPG2DDS safety study by Alloueche et al., Day 3 and
Day 14 data were sparse, but at Day 7 there was a significantly
larger decrease in mean hemoglobin with CPG2DDS than for the
comparator sulfadoxine2pyrimethamine (SP): treatment difference 24 g/L (95%CI 26, 22) [7]. In the current trial, the
difference between CDA and AL for Day 7 mean hemoglobin was
not greatly dissimilar when considering the overlap in 95%CIs:
27 g/L (95%CI 29, 24). However, the effect of the sparse
hemoglobin sampling in the Alloueche et al. study becomes evident
when the proportion of patients with hemoglobin decreases of
$20 g/L at any time point is examined; this was 16% for both
CPG2DDS and SP [7]. We know that both CPG2DDS and SP
cause hemolysis, and yet the proportion of patients in the current
study with hemoglobin decreases of $20 g/L was 33% for CDA
and 24% for AL. If the data sets were comparable, we would
expect CPG2DDS and SP to have results approximating those for
CDA, or at least a greater proportion of clinically important
hemoglobin decreases than with AL.
The position becomes even more complicated when the limited
analysis of hemoglobin declines by G6PD genotype in the
Alloueche et al. study is considered. G6PD status was assessed
retrospectively and only in a subset of patients, i.e. some patients
with a $20 g/L hemoglobin drop and matched controls (by age
and sex). There was no excess risk for a $20 g/L hemoglobin
drop with CPG2DDS versus SP in G6PD-normal or G6PDdeficient patients (classified as A2 or A2/A2). However, for
female heterozygotes, there was an excess risk with CD versus SP
[7]. Although this analysis can provide an idea of the risk of
haemolysis for CD relative to SP, it cannot give a true odds ratio
for the risk of haemolysis for G6PD-deficient relative to G6PDnormal patients. Moreover, the Alloueche et al. results are in direct
contrast to all of the G6PD-based analyses reported here, where
G6PD-deficient patients were at greater risk of hemolytic events
versus G6PD-normal and female heterozygote patients. Our study
indicates that frequent hemoglobin assessment plus comprehensive
PLoS ONE | www.plosone.org

Conclusion
To our knowledge, this is the first randomized controlled
clinical Phase III multi-centre study to include a component
investigating the relationship between hematological safety and
G6PD deficiency. There is no accepted in vitro test or in vivo
model to determine the potential for G6PD-related hemolysis.
G6PD genotyping and separate analysis of hemizygous males/
homozygous females versus heterozygote females and G6PDnormal patients was necessary to show the clinical importance of
the interaction between CDA and G6PD deficiency for hematological safety. Our results highlight that new antimalarials, such as
AL, may have significant safety as well as efficacy benefits over
older therapies, illustrating the need to conduct comprehensive
Phase III trials of antimalarial combination therapies against
relevant comparators, even when the components are already
approved individually. It also highlights the challenges of
developing therapies for populations harboring G6PD deficiency
and possibly other polymorphisms.
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